Spyre Therapeutics, Inc. Common Stock

Day range

$90.35 – $94.19

Open

$91.54

Prev close

$90.33

Volume

292.51K

Market cap

$8.44B

Shares out

101.91M

P/E

—

P/S

—

P/B

7.67

P/FCF

—

ROE

-13.6%

ROA

-12.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Capital allocation updateOct 7, 2026

  The gross proceeds to the Company from the Offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds to advance its Gastroenterology, Rheumatology, and Dermatology programs, develop SPY072, support general infrastructure, and potentially in-license, acquire, or invest in additional businesses, technologies, products, or assets.

• Clinical trial resultsSep 8, 2026

  Initial 12-week findings from SKYLINE Part A demonstrated that SPY003 met all key objectives. The study population consisted of 41% advanced therapy-exposed participants... SPY003 achieved the primary endpoint, demonstrating a statistically significant 10.0-point reduction in RHI score (p<0.0001), robust rates of clinical remission and endoscopic improvement, and a meaningful change in mMS.

• Clinical trial resultsAug 25, 2026

  The topline results from the RA sub-study of the Phase 2 SKYWAY basket trial indicated that both SPY072 Low Dose and SPY072 High Dose demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (ACR50). SPY072 was well tolerated, with a safety profile consistent with the TL1A class.

• Clinical trial resultsJun 15, 2026

  Initial 12-week findings from SKYLINE Part A demonstrated that SPY002 met all key objectives... SPY002 achieved the primary endpoint, demonstrating a statistically significant 10.7-point reduction in RHI score (p<0.0001), robust rates of clinical remission and endoscopic improvement, and a meaningful change in mMS, results that are among the highest reported in UC.

• Licensing agreementJun 1, 2026

  On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the Amended and Restated License Agreement dated as of February 24, 2025 (as amended, the "SPY003 License Agreement"), by and between the Company and Paragon Therapeutics, Inc. The Amendment, among other things, expands the definition of "Field" to encompass all therapeutic, prophylactic, palliative and diagnostic uses, subject to the restriction that the Company will not dose a human patient in a clinical trial of SPY003 for an indication outside of inflammatory bowel disease as part of a combination until June 1, 2028 or as a monotherapy until June 1, 2030.

Days to cover

8.9

Short interest

12.84M

Avg volume

1.44M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
  positiveGlobeNewswire Inc.· Oct 18, 2026
• Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Oct 5, 2026
• Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
  negativeZacks Investment Research· Sep 3, 2026
• Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Apr 14, 2026
• Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
  neutralBenzinga· Apr 13, 2026